Background: LncRNA LINC00461 has been reported to play crucial regulatory roles in a variety of biological processes, including cell migration, cell invasion and cancer progression. However, its biological role in colorectal cancer (CRC) is completely unknown. The aim of our study was to explore the function of LINC00461 on CRC cells and the underlying mechanism. Materials and methods: CRC tumor tissues and cell lines derived from hospital and corporation. The expression level of LINC00461 in CRC tissues and cell lines were analyzed by quantitative real-time PCR (qRT-PCR). The effect of LINC00461 on cell proliferation, colony formation, migration and invasion were detected by CCK-8 assay, colony formation and transwell assay, respectively. In addition, cell apoptosis was analyzed by flow cytometry, and the role of LINC00461 on tumor growth was investigated by tumor xenografts in nude mice. The targets of LINC00461 were predicted by starBase v3.0 and confirmed by a dual-luciferase reporter system. The expression level of transcription factors of nuclear factor I B (NFIB), p21 and CDK2 was determined by Western blot or qRT-PCR. The NFIB expression levels in CRC tissues and mice tumors were analyzed by immunofluorescence assay (IHC). Results: We found that the expression of LINC00461 was significantly overexpressed in CRC tissues and different cell lines, and the high level of LINC00461 expression was associated with poor overall survival. Downregulation of LINC00461 expression significantly suppressed the proliferation, migration and invasion of CRC cells and promoted cell apoptosis. We also found that LINC00461 could directly interact with miR-323b-3p. In addition, LINC00461 significantly increased the expression NFIB and CDK2, but, p21 was inhibited. Finally, we found that the growth of tumors in nude mice was suppressed upon LINC00461 deletion. Conclusion: We demonstrated that LINC00461 may play an oncogenic role in CRC cells through NFIB signaling pathway by targeting miR-323b-3p. Our report showed that LINC00461 may be a prognostic biomarker and candidate therapeutic target for CRC.
Introduction
As a kind of human cancer, colorectal cancer is the second cause about cancerrelated death in western countries. 1 Simultaneously, in China, death from colorectal cancer is also the fifth cause about cancer-related death 2 due to the lack of tumor diagnosis method to rapid cancer progression. 3 In addition, high mortality of CRC is a lack of availability of adequate prognostic biomarkers, high degree of metastasis capacity, poor prognosis and recurrence. Report showed that about 90% of early patients of CRC have a chance to survive by surgery. But, many patients have already diagnosed at advanced stages. 4 Despite chemotherapy, surgery and even immunotherapy are used to treat patients with CRC in current clinical treatments, the poor prognosis is not eliminated in patients with advanced disease. [5] [6] [7] That is why it is very necessary that further clarify the potential pathogenesis and explore predictive markers to improve the survival rate and prognosis of CRC patients. Long non-coding RNAs (lncRNAs) are made up of noncoding RNA with a length of more than 200 nucleotides, but no protein encoding function. 8 Accumulating evidence
revealed that the dysregulation of lncRNAs plays significant roles in many physiological and pathological processes of human diseases, especially in cancers. Some reports showed that lncRNAs are related to pathogenesis of cancers by promoting or inhibiting the onset of cancers, the dysregulation of lncRNAs expression can affect the cycle, proliferation, growth, apoptosis, metastasis and invasion of cancer cells by mediating epigenetic modifications and regulating transcriptional activities. 9 In recent years, studies about lncRNAs have attracted an ever-increasing number of attention due to its function on microRNA (miRNA). LncRNA can regulate the expression of protein by targeting miRNA. 9,10 LINC00461 was a newly identified LncRNA, studies indicated that the level of LINC00461 expression was upregulated in glioma, hepatocellular carcinoma and breast cancer. [11] [12] [13] But, the biological function of LINC00461 in CRC remains unclear.
In our work, results demonstrated that the expression of LINC00461 was substantially upregulated in tissue and cells of CRC, and it is related with the poor overall survival. We further explored the roles of LINC00461 on the CRC cells in vitro, results dedicated that LINC00461 can promote the cell proliferation, invasion and migration, but inhibit cell apoptosis by targeting miR-323b-3p that can target NFIB and regulating the expression of p21 and CDK2. The growth of CRC cells was significantly inhibited due to the silence of LINC00461 in vivo. Taken together, our study reveals that LINC00461 can be served as a candidate biomarker for CRC diagnosis and treatment.
Materials and Methods

Patients and Samples
Colorectal cancer tumor tissues of human and corresponding adjacent normal tissues were obtained from Peking Union Medical College. All patients did not undergo any treatment and provided written informed consent. This study was approved by the Ethics Committee of Chengde Medical Collage and Peking Union Medical College. All experiments involving human CRC tissues were performed in accordance with the Declaration of Helsinki.
Cell Culture
The human normal colonic epithelial cell NCM460, colonic cancer cell lines (DLD-1, RKO, HT29, and SW480) and HEK293T were purchased from the ScienCell Research Laboratories. All cells were cultured in DMEM medium (Gibco, USA) containing 10% FBS (Gibco, USA), and placed in a cell culture incubator with 5% CO 2 at 37°C.
RNA and qRT-PCR
In order to obtain RNA, cells and tumor issues were lysed by TRIzol (Invitrogen, USA) and reverse transcription was performed by a reverse transcription kit (Invitrogen, USA). SYBR-Green PCR Master Mix Kit (Takara, Japan) is used to perform Quantitative PCR on an ABI 7500 system (Applied Biosystems, Foster City, USA). The sequences of real-time PCR primers were presented as follows:
LINC00461: Forward (5ʹ-3ʹ) GACATTTACGCCACA ACCCACG;
Reverse (5ʹ-3ʹ): AGACAGACCCTCAGATTCCCCA. U6: Forward (5ʹ-3ʹ) CTCGCTTCGGCAGCACA; Reverse (5ʹ-3ʹ) AACGCTTCACGAATTTGCGT. NFIB: Forward (5ʹ-3ʹ) TGAGGCAGCTTCACCTAC AG;
Reverse (5ʹ-3ʹ) AGGATGGGTCTCTTGGGCTTA. GAPDH: Forward (5ʹ-3ʹ) GTCAACGGATTTGGTCT GTATT;
Reverse (5ʹ-3ʹ) AGTCTTCTGGGTGGCAGTAT. hsa-miR-323b-3p: Forward (5ʹ-3ʹ) TGCGGCCCAATA CACGGTCGACC;
Reverse (5ʹ-3ʹ) CCAGTGCAGGGTCCGAGGT.
Cell Transfection
si-LINC00461, miR-323b-3p mimic, miR-323b-3p inhibitor, and their negative control RNA (si-NC) were constructed and purchased from Jikai Chemical Technology (Shanghai, China). In order to overexpress LINC00461, full-length LINC00461 was cloned into the pcDNA3.1 vector (Genechem, Shanghai, China). Cells were transfected with si-NC, si-LINC00461, pcDNA3.1, pcLINC00461, miR-323b-3p mimics, miR-NC, miR-323b-3p inhibitor and inhibitor-NC using the Lipofectamine 2000 reagent (Invitrogen, USA), respectively. The transfection efficiency was analyzed by qRT-PCR assay after 48 h posttransfection. Colonies were fixed with 4% of paraformaldehyde for 10 min, stained with 1% crystal violet, and washed twice with PBS. Finally, cell colonies were imaged and counted.
Cell Viability Analysis
Cell Migration and Invasion
To assess the cell migration and invasion capability, transwell assay was performed, DLD-1 cells were transfected with different plasmid or si-RNA. Cells were suspended by medium without serum, 5×10 4 cells were seeded in the upper chamber. Cultured medium with 20% serum was placed in the lower chamber. Then, noninvading and nonmigrating cells were cleared after 48 h. Remaining cells were fixed with 4% of paraformaldehyde for 15 min, the membranes were stained with 0.1% crystal violet solution for 30 min. Then, the stained cells were captured using a microscope and counted.
Dual-Luciferase Reporter Assay
We seeded DLD-1 cells in a 96-well plate (5000 cells/ well). Then, cells were co-transfected with luciferase reporter plasmids of LINC00461-wild type or LINC00461-mutant type and miR-323b-3p mimics or miR-NC using RNAiMAX Reagent (Thermo Scientific, USA) according to the reagent instruction. Luciferase activities were detected by a microplate reader of a multiwavelength measurement system (Bio-Rad, USA) at 48 h post-transfection. Similarly, NFIB-wild type or NFIBmutant type luciferase reporter plasmids were cotransfected with miR-323b-3p mimics or miR-NC into HEK293T cells, luciferase activities were measured as previously described.
Flow Cytometric Analysis of Apoptosis
To evaluate the effect of LINC00461 to cell apoptosis, the cell apoptosis assay was performed by a FITC Annexin V Apoptosis Detection Kit (BD Biosciences, USA) according to the manufacturer's instruction. DLD-1 cells transfected with si-NC or si-LINC00461 for 48 h, then cells were collected and stained with Annexin V for 10 min and Propidium Iodide (PI) for 5 min in the dark. Last, the percentage of apoptotic cells was measured using a BD FACSCalibur flow cytometer (BD Biosciences, USA).
Western Blot
Cells were lysed with RIPA lysis buffer (Solarbio), protein samples were subjected to Western blot with primary antibody for anti-NFIB (Abcam, UK), anti-p21 (Abcam, UK), anti-CDK2 (Abcam, UK), anti-GAPDH (Abcam, UK) and secondary antibody.
Tumor Xenografts in Nude Mouse
All animal experiments in this study were performed according to guidelines of the NIH for the care and use of laboratory animals and approved by the Animal Ethics Committee of Chengde Medical Collage. si-NC or si-LINC00461 was transfected into DLD-1 cells, and cells were subcutaneously injected into female BALB/c nude mice (4-week old, n=10). Tumor size was measured after injection and growth curves were plotted. Tumor volume was calculated according to the formula: Volume = Length×Width×Width×1/2. At postinjection 28 days, mice were sacrificed, and other experiments were performed.
Immunohistochemistry
In order to detect the expression of NFIB in tumor tissues, we performed immunohistochemistry assays (IHC) according to previously described method. 14 The primary and secondary antibodies in Western blot were also used for Immunohistochemistry.
Lung Metastatic Mouse Model
DLD-1 cells were transfected with si-NC or si-LINC00461 and injected into nude mice via tail vein (4×10 6 cells/ 200 µL PBS/mouse). All mice were sacrificed after 40 days, lung tissues were harvested and imaged, and the number of metastatic lesions in the lungs was counted to evaluate the role of LINC00461 on CRC lung metastasis.
Statistical Analysis
All data were presented as mean ± SD. Differences between two experimental groups were analyzed by a paired t-test. P < 0.05 is considered to have significant statistical differences.
Results
LINC00461 Was Upregulated in Human CRC Tissues and Cell Lines
To investigate the role of LINC00461 in CRC, the expression level of LINC00461 was examined from 30 patients with CRC. Quantitative PCR showed that higher expression of LINC00461 in the CRC tumour tissues instead of adjacent tissues ( Figure 1A ). The expression of LINC00461 was also analyzed in CRC cell lines (RKO, HT29, DLD-1 and SW480) and a normal cell line (NCM460). We found that the LINC00461 expression level was highly increased in cancer cells ( Figure 1B) . Furthermore, we found that LINC00461 expression was positively along with the progress of cancer, the expression level of LINC00461 in III/IV stages was obviously higher than I/II stages ( Figure 1C ). Meanwhile, we further analyzed the survival rate of patients. Result showed that downregulation of LINC00461 had higher survival rates than high LINC00461 expression ( Figure 1D ). Those results showed that LINC00461 might be related to CRC progress. (Figure 2A and D) . Our results showed that the proliferation capacity of cells was significantly suppressed after transfected with si-LINC00461 as compared with control group ( Figure 2B ). As we expected, the overexpression of LINC00461 prominently promoted the proliferation capacity of cells ( Figure 2E ). Simultaneously, we further explored the role of LINC00461 to cells on mesenchymal features. Results indicated that the expression of Vimentin and N-cadherin was reduced, but the expression of E-cadherin was increased when cells transfected with si-LINC00461 ( Figure 2C ). On the contrary, these appearances in Figure 2C were reversed in cells transfected with LINC00461 overexpression plasmids ( Figure 2F ). Next, colony formation and transwell assays showed that the downregulation of LINC00461 expression level extremely suppressed colony formation, migration and invasion capacities of CRC cells ( Figure 2G and H) . Finally, the function of LINC00461 to cell apoptosis was explored with flow cytometry. We found that cell apoptosis rates were substantially increased when cells were transfected with si-LINC00461 ( Figure 2I and J). In summary, these results indicated that LINC00461 can regulate cell colony formation, apoptosis, migration and invasion.
LINC00461 Directly Interacts with miR-323b-3p in CRC
Many studies showed that lncRNAs can be combined with miRNAs with complementary base pairing way. To predict potential targets of LINC00461, the potential miRNAs were predicted by starBase v3.0. A potential complementary binding site of miR-323b-3p and LINC00461 as shown in Figure 3A . To prove it, luciferase reporter experiments were carried out. DLD-1 cells were transfected with luciferase reporter plasmids and miR-323b-3p mimics. Results showed that luciferase activity decreased for cells transfected with wild-type vector. But the luciferase activity of mutant-type vector no affected ( Figure 3B ). In addition, we also detected the expression of miR-323b-3p in tumor tissues of CRC and cell lines. Our results showed that the expression of miR-323b-3p was decreased in tumor tissues of CRC and cell lines ( Figure 3C and D). Simultaneously, spearman correlation test demonstrated that LINC00461 was negatively correlated with miR323b-3p in tissues of CRC ( Figure 3E ). Furthermore, we found that the downregulation of LINC00461 leads to the increasement of miR-323b-3p in DLD-1 and SW480 cells ( Figure 3F ). While the expression of LINC00461 was down-regulated when miR-323b-3p mimics were transfected into HT29 and RKO cells ( Figure 3G ). In addition, we demonstrated that cell proliferation capacity was significantly suppressed in DLD-1 cells transfected with miR323b-3p mimics, the opposed results were found in DLD-1 cells transfected with miR-323b-3p inhibitor ( Figure 3H ). Rescue assay also indicated LINC00461 and miR-323b-3p can reciprocally reverse the respective inhibition effect for DLD-1 cell proliferation ( Figure 3I and J). These data suggest that LINC00461 can directly interact with miR323b-3p and correlated negatively with miR-323b-3p.
miR-323b-3p Inhibits CRC Progression by Targeting NFIB
To identify potential target genes of miR-323b-3p, bioinformatic analysis starBase v3.0 predicted that miR-323b-3p directly targets NFIB ( Figure 4A ). HEK293T cells were transfected with NFIB luciferase reporter plasmids and miR-323b-3p mimics. Results indicated that overexpression of miR-323b-3p highly reduced fluorescence intensity in cells transfected with wild-type vector ( Figure 4B ). In addition, qRT-PCR indicated that the expression of NFIB was increased in CRC cell lines ( Figure 4C ). Furthermore, Western blot analysis and qRT-PCR also has proven that the expression of NFIB was reduced in cells transfected with miR-323b-3p mimics ( Figure 4D and E). But inhibitory effect was abolished in cells transfected with miR323b-3p inhibitor ( Figure 4F and G). Next, in order to further explore the roles of LINC00461 on NFIB expression, the CRC cells were transfected with si-LINC00461 or pcLINC00461. Results showed that the down expression of LINC00461 has significantly decreased NFIB expression, we also observed the expression of p21 (a direct target of NFIB 15 ) was induced, CDK2 (cyclindependent kinase 2, combination of p21 and CDK2 leads to cell cycle arrest. 16 ) was suppressed upon LINC00461 deletion ( Figure 4H ). On the contrary, NFIB expression was increased in cells with high LINC0046 expression, however, p21 and CDK2 presented the opposite results as compared with Figure 4H upon LINC00461 overexpression ( Figure 4I ). Tissue immunofluorescence assay also showed that NFIB was induced in tumor tissues of CRC patients ( Figure 4J ). Spearman correlation test has also indicated the positive correlation between LINC00461 and NFIB ( Figure 4K ). Collectively, these data indicated that NFIB can server as a target of miR-323b-3p.
Downregulation of LINC00461 Inhibits Tumor Growth
Lastly, the function of LINC0046 on tumor was investigated in vivo. Nude mice were subcutaneously injected with DLD-1 cells transfected with si-NC or si-LINC00461. We found that the growth of tumor in si-LINC00461 group was slower than si-NC group ( Figure 5A ). The weight of the tumor was measured at 28 days post-injection. Results indicated that tumor weight in si-LINC00461 group was obviously less than si-NC group ( Figure 5B ). The high expression of NFIB was also found by IHC in tumor issues of mice transfected with si-NC instead of si-LINC00461 ( Figure 5C ). Interestingly, tumor metastases assay also indicated the knockdown LINC00461 inhibited the lung metastasis of CRC ( Figure 5D and E). These data demonstrated that downregulation of LINC00461 obviously suppressed CRC progression in vivo. At last, the schematic illustration of LINC00461 regulating miR-323b-3p/NFIB axis showed in Figure 5F .
Discussion
A lot of researches have indicated that lncRNAs are closely involved in the human diseases. As oncogenes or cancer suppressor genes, the dysregulation of lncRNAs expression was closely related with the progression of cancers. 17, 18 LncRNAs with significant roles in growth characteristics of cancer cells can regulate the epithelial-mesenchymal transition (EMT), metastasis, apoptosis, migration and invasion. [19] [20] [21] In this study, we found that LINC00461 expression was significantly increased in tumor tissues and cell lines of CRC. In addition, the poor OS of patients with CRC was correlated with high LINC00461 expression. The proliferation, migration and invasion capacities were inhibited in CRC cells transfected with si-LINC00461. However, the effect was significantly reversed by the upregulation of LINC00461. Some reports have demonstrated that LINC00461 was associated with the progress of various cancers by targeting miRNA. For example, Ji et al reported that LINC00461 have a high expression level in hepatocellular carcinoma, it positively correlated with advanced stage, poor prognosis and metastasis. 12 Dong et al reported that LINC00461 exerted a promoted effect in breast cancer by enhancing cell migration and invasion. 13 Interestingly, Gao et al showed that LINC00461 was related to macular thickness at genomewide, characterized by elevated expression of LINC00461 in the retina, which indicated that LINC00461 also exerted function in other human disease. 22 Deng et al demonstrated that high LINC00461 expression dramatically promoted cell proliferation and suppressed cell apoptosis in multiple myeloma in the way of regulating miR-15a/miR-16 on BCL-2. 23 Yang et al indicated that LINC00461 enhanced the progress of glioma by mediating AMAPK/ERK and PI3K/AKT signaling pathways. 11 In this work, we found that cell viability, invasion and migration capacities were obviously suppressed for the LINC00461 downregulation in vitro and in vivo, and cell apoptosis was promoted.
To explore the potential roles of LINC00461 on CRC, starBase v3.0 is used to predict the targets of LINC00461. We found that miR-323b-3p could be a target and based on its biological function in cancers. Xie et al reported that miR-323b-3p can regulate osteosarcoma (OS). TGFBR3, a target of miR-323b-3p, was inhibited at the early stage of OS. But, TGFBR3 was promoted by miR-323b-3p in the advanced stage of OS. So, miR-323b-3p plays a dual role in different stages of OS by mediating TGF-β signaling pathway. 24 In addition, the expression of miR-323b-3p is significantly increased and closely correlated with metastasis and poor prognosis of lung adenocarcinoma, and genomic hypomethylation. 25 miR-323b-3p was also reported to may be associated with lupus nephritis. 26 However, study showed that down-regulation of miR323b-3p expression may be related to the progress of diffuse large B-cell lymphoma. 27 NFIB was reported to regulate many cellular gene expression. 28 Reports showed that NFIB plays a vital role in tumor progression. Liu et al showed that NFIB exerted positive role in the progress of triple-negative breast cancer by promoting cell survival. 15 Campbell et al demonstrated that NFIB and YBX1 have affected the breast cancer progress by binding ERα, leading to FGFR2 to modulate estrogen responsiveness. 29 In addition to the descriptions above, NFIB also be reported to regulate other cancer progressions in glioma, glioblastoma and osteosarcoma. 14, [30] [31] [32] But the relationship between NFIB and miR-323b-3p is still unknown in CRC. In our study, we indicated that LINC00461 enhanced CRC progress by miR-323b-3p/NFIB axis.
Conclusion
In conclusion, our study first demonstrated that LINC00461 as an oncogenic promoted the proliferation, migration and invasion, and inhibited apoptosis of CRC cells by regulating the expression of miR-323b-3p, NFIB, p21 and CDK2. Our study may provide a reference for the diagnosis and treatment of CRC.
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